Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. The company’s lead approved product is ZEVASKYN, an autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. ZEVASKYN is manufactured at the company’s current Good Manufacturing Practices facility in Cleveland Ohio and is administered through a network of qualified treatment centers. In addition to its commercial product Abeona maintains a research and development pipeline focused on adeno-associated virus based gene therapies that utilize the company’s AIM™ capsid platform to target ophthalmic conditions such as X-linked retinoschisis Stargardt disease and autosomal dominant optic atrophy. The company partners with academic institutions patient advocacy groups and other biotechnology firms to advance its programs and seeks to protect its innovations through a robust intellectual property portfolio.

Abeona Therapeutics Inc. generates revenue primarily from the sale of ZEVASKYN to qualified treatment centers that administer the therapy to eligible patients. The company also receives income from licensing agreements that provide upfront payments milestone payments and royalties on net sales of products that incorporate its AIM™ capsid technology or other proprietary assets. Notable licensing arrangements include a non-exclusive agreement with Beacon Therapeutics for the AAV204 capsid and out-licenses to Ultragenyx Pharmaceutical Inc. and Taysha Gene Therapies Inc. for specific gene therapy programs. In addition Abeona realized a one-time proceeds from the sale of a Priority Review Voucher awarded upon ZEVASKYN’s approval. Revenue is further supported by broad insurance coverage including Medicare Medicaid and private insurers that reimburse for the administration of ZEVASKYN at certified centers.

Abeona Therapeutics Inc. occupies a distinctive position in the cell and gene therapy sector as the developer of the first and only FDA-approved autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa. The product benefits from orphan drug designation which provides a period of market exclusivity and regulatory incentives that reduce competitive pressure. While other companies such as Krystal Biotech with its topical gene therapy Vyjuvek and traditional gene therapy firms like Spark Therapeutics and Regenxbio pursue overlapping therapeutic areas Abeona differentiates itself through its integrated manufacturing capabilities its proprietary AIM™ capsid library and its extensive patent estate covering vector design manufacturing processes and clinical applications. These assets enable the company to control supply chain quality and to pursue multiple therapeutic indications simultaneously.

The company’s customer base consists of patients with recessive dystrophic epidermolysis bullosa who receive ZEVASKYN through a network of qualified treatment centers. As of March 2026 Abeona had activated four centers including Ann & Robert H. Lurie Children’s Hospital of Chicago Lucile Packard Children’s Hospital Stanford Children’s Hospital Colorado and the University of Texas Medical Branch in Galveston Texas. These centers are selected for their expertise in cell and gene therapy and have undergone specific training to administer the therapy. In addition to patient customers Abeona serves licensing partners such as Beacon Therapeutics Ultragenyx and Taysha which pay fees and royalties for the use of its proprietary technologies. Reimbursement for ZEVASKYN is obtained from governmental payers including the Centers for Medicare and Medicaid Services and Medicaid programs across all fifty states and Puerto Rico as well as from numerous national and regional commercial health insurers.